GLYC-101: Completed Phase IIb enrollment

Glycotex completed enrollment of 12 patients undergoing carbon dioxide laser skin resurfacing in a double-blind, placebo-controlled, U.S. Phase IIb trial of topical GLYC-101. Novogen owns an 81% stake...